Pralatrexate information

Pralatrexate
Clinical data
Trade names	Folotyn
AHFS/Drugs.com	Monograph
License data	US FDA: Pralatrexate;
Routes of; administration	Intravenous
ATC code	L01BA05 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only;
Identifiers
	IUPAC name N-(4-{1-[(2,4-diaminopteridin-6-yl)methyl]but-3-yn-1-yl}benzoyl)-L-glutamic acid;
CAS Number	146464-95-1 ;
PubChem CID	148121;
IUPHAR/BPS	6840;
DrugBank	DB06813 ;
ChemSpider	130578 ;
UNII	A8Q8I19Q20;
KEGG	D05589;
ChEBI	CHEBI:71223 ;
ChEMBL	ChEMBL1201746 ;
CompTox Dashboard (EPA)	DTXSID3048578 ;
ECHA InfoCard	100.205.791
Chemical and physical data
Formula	C23H23N7O5
Molar mass	477.481 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)[C@@H](NC(=O)c1ccc(cc1)C(CC#C)Cc2nc3c(nc2)nc(nc3N)N)CCC(=O)O;
	InChI InChI=1S/C23H23N7O5/c1-2-3-14(10-15-11-26-20-18(27-15)19(24)29-23(25)30-20)12-4-6-13(7-5-12)21(33)28-16(22(34)35)8-9-17(31)32/h1,4-7,11,14,16H,3,8-10H2,(H,28,33)(H,31,32)(H,34,35)(H4,24,25,26,29,30)/t14?,16-/m0/s1 ; Key:OGSBUKJUDHAQEA-WMCAAGNKSA-N ;
	(what is this?) (verify)

Pralatrexate, sold under the brand name Folotyn, is a medication used for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL).^[3]^[4]

Pralatrexate was approved for medical use in the United States in September 2009, as the first treatment for Peripheral T-cell Lymphoma (PTCL), an often aggressive type of non-Hodgkins lymphoma.^[4]^[5]

^ "Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
^ "Summary Basis of Decision (SBD) for Folotyn". Health Canada. 23 October 2014. Retrieved 29 May 2022.
^ "Folotyn- pralatrexate injection". DailyMed. 28 May 2020. Retrieved 21 October 2020.
^ ^a ^b Cite error: The named reference FDA PR was invoked but never defined (see the help page).
^ Cite error: The named reference FDA approval package was invoked but never defined (see the help page).

[1] "Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.

[2] "Summary Basis of Decision (SBD) for Folotyn". Health Canada. 23 October 2014. Retrieved 29 May 2022.

[Folotyn_FDA_label-3] "Folotyn- pralatrexate injection". DailyMed. 28 May 2020. Retrieved 21 October 2020.

[FDA_PR-4] Cite error: The named reference FDA PR was invoked but never defined (see the help page).

[FDA_approval_package-5] Cite error: The named reference FDA approval package was invoked but never defined (see the help page).

Pralatrexate information

and 26 Related for: Pralatrexate information

Pralatrexate

List of antineoplastic agents

Methotrexate

Quercetin

Tretinoin

Nucleotide

Purine

Fenethylline

Allopurinol

Abemaciclib

Celecoxib

Uric acid

Inositol

Phenolphthalein

Cancer immunotherapy

Lisocabtagene maraleucel

Febuxostat

Cytosine

Guanine

Venetoclax

Pentoxifylline

Caffeine

Cytarabine

Carboplatin

Mitomycin C

Cytidine monophosphate